Featured Dec 19 Astellas pays Sangamo $20M upfront to improve neurological gene therapy capabilities read more » Dec 17 Phase 1/2 trial data may support AMT-130 approval, FDA says read more » Dec 16 Genprex Receives Safety Review Committee Approval to Advance to Phase...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a leader in genomic medicine, and Astellas Pharma Inc. (TSE: 4503), a global innovator in life sciences, have partnered under a new license agreement. This collaboration centers around Sangamo’s cutting-edge neurotropic AAV...
Hearing loss affects millions of people worldwide and can be caused by genetic defects in key proteins essential for auditory function. Recent research by Pedro De-la-Torre and colleagues (doi: https://doi.org/10.1101/2024.06.16.599132) has provided significant...
Credit: Pixabay/CC0 Public Domain A team of Children’s Medical Research Institute (CMRI) scientists has identified a new method for producing a therapeutic product that has the potential to improve the treatment of cancer. The work by Associate Professor Leszek...
The U.S. Food and Drug Administration (FDA) has agreed that data from two ongoing Phase 1/2 clinical trials, compared with an external control group of untreated patients, may suffice to support an accelerated approval application for a groundbreaking gene therapy for...
